完全ヒト抗体/ TCRプラットフォーム

モノクローナル抗体

モノクローナル抗体(mAb)は、高い特異性、持続的な有効性、そして高い安全性を特徴とし、オフターゲット効果を最小限に抑えながら正確な標的化を可能にします。腫瘍学をはじめとする様々な疾患において広く利用されており、二重特異性抗体(ADC)への改変も可能であるため、プレシジョン・メディシン(精密医療)の基盤となっています。
  • 1000+
    標的プロジェクト
  • 1M
    完全ヒト型
    抗体配列
  • 450+
    抗体アセットパートナーシップ

このページで

  • mAbプラットフォームの特徴
  • RenMabベースのmAbsプラットフォーム
  • FAQs

ポスター

すべて表示

    mAbsプラットフォームの特徴

    • RenMabによって生成された高親和性の完全ヒト抗体は、ヒト化の必要がなく、開発期間を短縮します。
    • GPCR、イオンチャネル、腫瘍微小環境関連抗原などの複雑なターゲットの抗体開発をサポートし、広範な適用可能性を確保します。
    • このプラットフォームは、in vitroおよびin vivoでの機能検証、有効性試験、モデル評価を統合しており、候補分子の選定と最適化を加速します。
    • 抗体の探索から前臨床検証まで、エンドツーエンドのサービスを提供し、共同開発、ライセンス供与、戦略的パートナーシップをサポートします。

    RenMabベースのmAbsプラットフォーム

    RenLiteマウスから開発されたBsADC

    MAbs developed from RenMab mice img

    Frequently Asked Questions (FAQs) About Monoclonal Antibody Platform

    1. What are monoclonal antibodies, and how can they support drug development?

    Monoclonal antibodies (mAbs) are antibodies derived from a single clone that recognize a specific epitope on a target antigen. As therapeutics, they can block signaling, neutralize disease-related molecules, or recruit immune responses. Beyond conventional applications, they can also serve as building blocks for antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), antibody-peptide conjugates (APCs) and bispecific antibodies. Their variable regions can be engineered into single-chain variable fragments (scFvs) that serve as antigen-recognition domains in CAR-T therapies.

    2. What types of targets can Biocytogen’s monoclonal antibody platform support?

    Biocytogen’s RenMab® platform generates fully human antibodies against a broad range of therapeutic targets, including GPCRs, ion channels, and tumor microenvironment-associated antigens. For highly conserved targets, RenMab® target gene knockout mice (RenMab® KO) can overcome immune tolerance and broaden epitope coverage.

    3. What factors should guide therapeutic monoclonal antibody candidate selection?

    Selecting therapeutic mAb candidates requires evaluating target relevance, binding affinity and specificity, functional activity, preclinical efficacy, pharmacokinetics, safety, and immunogenicity risk. Developability, including stability, solubility, aggregation propensity, and manufacturability, is also essential.
    Partners can request asset-specific data packages from Biocytogen to assess available evidence and select candidates aligned with their therapeutic goals and development requirements.

    4. Can monoclonal antibodies be developed into other therapeutic formats?

    Yes. RenMab®-derived monoclonal antibody binders can serve as building blocks for other therapeutic formats, including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), antibody-peptide conjugates (APCs), bispecific antibodies and scFv, the key recognition elements of CAR-T. Biocytogen also provides off-the-shelf antibody binders and other discovery platforms to support different molecular design: RenLite® generates fully human common light chain antibodies for bispecific antibodies and BsADCs, while RenNano® generates fully human HCAbs and VHHs.

    5. What collaboration options does Biocytogen offer for monoclonal antibody development?

    Biocytogen supports flexible collaboration opportunities for monoclonal antibody assets from early evaluation to clinical development. Partners can review available assets and evaluate selected candidates through material transfer agreements (MTAs). Following successful evaluation, assets can be licensed through collaboration agreements with upfront and milestone payments to advance selected assets.